Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Epidiolex® (cannabidiol) – DEA Descheduling
April 6, 2020 - GW Pharmaceuticals announced that it received notification from the Drug Enforcement Administration (DEA) confirming that Epidiolex (cannabidiol) is no longer subject to the Controlled Substances Act (CSA).
